{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:05:04Z","timestamp":1766361904462,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejphar.2019.172890","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:47:31Z","timestamp":1577105251000},"page":"172890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Analgesic and antiallodynic activity of novel anticonvulsant agents derived from 3-benzhydryl-pyrrolidine-2,5-dione in mouse models of nociceptive and neuropathic pain"],"prefix":"10.1016","volume":"869","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-1682","authenticated-orcid":false,"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Obniska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Jod\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"G\u00f3ra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Koczurkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172890_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(03)01933-2","article-title":"Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats","volume":"473","author":"Ardid","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib2","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/01.j.pain.0000460358.01998.15","article-title":"Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?","volume":"156","author":"Attal","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172890_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2019.172890_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.pharep.2016.01.001","article-title":"Antinociceptive activity of intraperitoneally administered novel and potent anticonvulsive compound, CY-PROLL-SS, in animal neuropathic pain models","volume":"68","author":"Bujalska-Zadro\u017cny","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2019.172890_bib5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib6","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejphar.2019.172890_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14737175.2017.1370375","article-title":"Pharmacological treatment of trigeminal neuralgia","volume":"17","author":"Di Stefano","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejphar.2019.172890_bib8","doi-asserted-by":"crossref","DOI":"10.4065\/mcp.2009.0649","article-title":"Recommendations for the pharmacological management of neuropathic pain: an overview and literature update","volume":"85","author":"Dworkin","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejphar.2019.172890_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pain.2004.01.029","article-title":"Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy","volume":"109","author":"Flatters","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172890_bib10","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.2174\/0929867326666190107163756","article-title":"Management of peripheral neuropathy induced by chemotherapy","volume":"26","author":"Fradkin","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejphar.2019.172890_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728214.2014.915025","article-title":"Emerging drugs for neuropathic pain","volume":"19","author":"Gilron","year":"2014","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejphar.2019.172890_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","article-title":"Drug development for refractory epilepsy: the past 25 years and beyond","volume":"44","author":"Golyala","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.ejphar.2019.172890_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejphar.2019.172890_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejphar.2011.11.026","article-title":"Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain","volume":"674","author":"Hamidi","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib16","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, synthesis and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides","volume":"58","author":"Kami\u0144ski","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bmc.2015.12.027","article-title":"New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones","volume":"24","author":"Kami\u0144ski","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.phrs.2016.11.030","article-title":"Brennan, sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain","volume":"117","author":"Kaufmann","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2019.172890_bib19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/j.pain.0000000000001524","article-title":"Targeting the CaV\u03b1-CaV\u03b2 interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy","volume":"160","author":"Khanna","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2019.172890_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s12885-019-5522-7","volume":"19","author":"Kneis","year":"2019","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejphar.2019.172890_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13181-017-0626-4","article-title":"The pharmacology and toxicology of third-generation anticonvulsant drugs","volume":"13","author":"LaPenna","year":"2017","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.ejphar.2019.172890_bib22","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2019.172890_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejphar.2019.172890_bib24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/head.13375","article-title":"Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018","volume":"3","author":"Loder","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2019.172890_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11940-015-0381-2","article-title":"Treatment of neuropathic pain","volume":"17","author":"Mendlik","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejphar.2019.172890_bib26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2019.172890_bib27","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.bmc.2016.02.026","article-title":"Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids","volume":"24","author":"Obniska","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.07.017","article-title":"Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid","volume":"102","author":"Obniska","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1254\/jphs.14058FP","article-title":"Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice","volume":"125","author":"Ohsawa","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2019.172890_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11940-019-0558-1","article-title":"Current status of antiepileptic drugs as preventive migraine therapy","volume":"21","author":"Parikh","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejphar.2019.172890_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2019.172890_bib32","first-page":"1069","article-title":"Advances and limitations in pharmacotherapy of epilepsy","volume":"75","author":"Rapacz","year":"2018","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.ejphar.2019.172890_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eplepsyres.2018.03.024","article-title":"Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides","volume":"143","author":"Rapacz","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2019.172890_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00210-017-1358-3","article-title":"Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy","volume":"390","author":"Rapacz","year":"2017","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2017.12.036","article-title":"Antiallodynic and antihyperalgesic activity of new 3,3-diphenyl-propionamides with anticonvulsant activity in models of pain in mice","volume":"821","author":"Rapacz","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2016.04.033","article-title":"Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice","volume":"781","author":"Rapacz","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00210-015-1194-2","article-title":"Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione","volume":"389","author":"Rapacz","year":"2016","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1039\/C6MD00537C","article-title":"Design, synthesis and anticonvulsant-analgesic activity of new N-[(phenoxy)alkyl]- and N-[(phenoxy)ethoxyethyl]aminoalkanols","volume":"8","author":"Rapacz","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejphar.2019.172890_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/epi4.12268","article-title":"Brief history of anti-seizure drug development","volume":"3","author":"Rho","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ejphar.2019.172890_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2019.172890_bib41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3109\/14756366.2015.1088842","article-title":"Synthesis and anticonvulsant activity of new N-mannich bases derived from benzhydryl- and isopropyl-pyrrolidine-2,5-dione","volume":"31","author":"Rybka","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172890_bib42","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.bmcl.2017.02.002","article-title":"Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs","volume":"27","author":"Rybka","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172890_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2019.172890_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuropharm.2017.07.022","article-title":"Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain","volume":"125","author":"Sa\u0142at","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.172890_bib45","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1345\/aph.1Q032","article-title":"Pregabalin-induced hepatotoxicity","volume":"45","author":"Sendra","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172890_bib46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2019.172890_bib47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2019.172890_bib48","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s11064-017-2286-9","article-title":"Preclinical comparison of mechanistically different antiseizure, antinociceptive, and\/or antidepressant drugs in a battery of rodent models of nociceptive and neuropathic pain","volume":"42","author":"Smith","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2019.172890_bib49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2019.172890_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpain.2005.04.002","article-title":"Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain","volume":"10","author":"St\u00f6hr","year":"2006","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejphar.2019.172890_bib51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biopha.2018.12.085","article-title":"An overview of tramadol and its usage in pain management and future perspective","volume":"111","author":"Subedi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172890_bib52","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1111\/j.1526-4610.2005.4501006.x","article-title":"Molecular pharmacology of topiramate: managing seizures and preventing migraine","volume":"45","author":"White","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2019.172890_bib53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.neuropharm.2017.06.027","article-title":"Bortezomib induces neuropathic pain through protein kinase C-mediated activation of presynaptic NMDA receptors in the spinal cord","volume":"123","author":"Xie","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2019.172890_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00210-013-0853-4","article-title":"Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties","volume":"386","author":"Ximenes","year":"2013","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172890_bib55","doi-asserted-by":"crossref","first-page":"e1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919308428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919308428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:31:35Z","timestamp":1757975495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919308428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":55,"alternative-id":["S0014299919308428"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172890","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analgesic and antiallodynic activity of novel anticonvulsant agents derived from 3-benzhydryl-pyrrolidine-2,5-dione in mouse models of nociceptive and neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172890"}}